Cadila Of India Shows Promising Test Results For “Polypill”
This article was originally published in PharmAsia News
Executive Summary
India's Cadila Pharmaceuticals appears to have a five-drug combination capable of reducing heart disease, according to early clinical trial results. Dubbed the "polypill," it combines blood-pressure, cholesterol-lowering and aspirin drugs into a single pill to reduce heart disease. The trial of just over 2,000 patients showed the combination was capable of reducing heart disease by 60 percent and strokes by half. Cadila sponsored the study of the combination pill, to be provided in a capsule it calls Polycap. (Click here for more
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.